SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...

The results of the phase 3 PATINA trial presented by Otto Metzger, M.D., medical oncologist at Dana-Farber Cancer Institute ...

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial.

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating ...

In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a ...

Biovica signed an agreement with US Biotech company in clinical phase Biovica received a significant order for TKa testing services Biovica published the outcome of exercise of warrants from series ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE®) to current standard-of-care ...

ShorePoint Inc., an industry-leading cybersecurity services company protecting federal customers' critical assets, today ...